Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 322 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vancomycin hydrochloride Clear all

Conditions: Clostridium Difficile Infection Recurrence
Interventions: FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more

Conditions: Clostridium Difficile Infection, Diarrhea
Interventions: Oral Vancomycin, Placebo, Toxin enzyme immunoassay, Nuceleic acid amplification test; Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pre-Diabetes
Interventions: Vancomycin, Placebo, Neomycin, Clindamycin, Fecal Microbiota Transplantation; Drug · Other · Procedure
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Dietary Modification
Interventions: Carnitine, Choline, Antibiotics, Choline and Aspirin, Carnitine and Aspirin; Dietary Supplement · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Influenza
Interventions: Synbiotic AKSB; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bacterial Infections, Wounds
Interventions: Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R), Placebo, complex gel formulation without Vancomycin; Drug
Lead sponsor: Robert S Berman MD; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Jupiter, Florida

Conditions: Peritoneal Dialysis-associated Peritonitis
Interventions: Vancomycin; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Osteomyelitis
Interventions: Intravenous Antibacterial Agent, Oral Antibacterial Agent; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Interventions: Vancomycin (POC); Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 65 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: Glen Burnie, Maryland

Conditions: Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis, Ulcer, Wound Infections
Interventions: Telavancin, Vancomycin or antistaphylococcal penicillin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
Interventions: KB109, No intervention; Other
Lead sponsor: Kaleido Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: Torrance, California • Atlanta, Georgia • Augusta, Georgia + 5 more

Conditions: Post Operative Surgical Site Infection
Interventions: Standard of care, Vancomycin and Tobramycin; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 64 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 31
States / cities: Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more

Conditions: Osteomyelitis Tibia, Tibial Fractures, Open Tibia Fracture
Interventions: Antibiotic coated intramedullary Nail, Standard Intramedullary Nail; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 15
States / cities: Gainesville, Florida • Temple Terrace, Florida • Macon, Georgia + 12 more

Conditions: Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions: IV Dalbavancin, Vancomycin/Linezolid; Drug
Lead sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 30
States / cities: Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more

Conditions: Antibiotic Resistant Strain
Interventions: Encapsulated fecal microbiota preparation, Encapsulated placebo; Biological
Lead sponsor: Microbiome Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Indianapolis, Indiana • Madison, Wisconsin

Conditions: Pharmacokinetics and Pharmacodynamics
Interventions: Vancomycin (IV); Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 50 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Red Man Syndrome
Interventions: Not listed
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 6 Months to 21 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Osteomyelitis, Methicillin-resistant Staphylococcus Aureus
Interventions: trimethoprim-sulfamethoxazole, vancomycin; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis, Hip Infection, Prosthetic Joint Infection, Complications; Arthroplasty, Infection or Inflammation, Complications; Arthroplasty
Interventions: Implantation of a static, non-articulating cement spacer., Implantation of an articulating spacer.; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation
Interventions: Vancomycin; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Streptococcal Sepsis, Hematologic Malignancies
Interventions: Empirical Vancomycin, Prophylactic Vancomycin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: VE303, Oral Vancomycin; Drug
Lead sponsor: Vedanta Biosciences, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, Pseudomonas Aeruginosa, VRE Infection, Methicillin-resistant Staphylococcus Aureus
Interventions: PMT; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Clostridium Infections, Diarrhea
Interventions: PAR-101/OPT-80, Vancomycin; Drug
Lead sponsor: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 16 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 53
States / cities: Gadsden, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 50 more

Search by objective public record fields.

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment

Interventional Bioremediation of Microbiota in Metabolic Syndrome

CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease

Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly

Effects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)

Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis

Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis

Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization

Vancomycin Dose Optimization in Obesity

Vancomycin Associated Red Man Syndrome (RMS)

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis

Study of Antibiotic Spacer Design to Treat Infection After Hip Replacement

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation

First-in-human Study of VE303 in Healthy Adult Volunteers

PMT for MDRO Decolonization

PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)